QT Imaging Holdings Inc

Análisis de la acción QT Imaging Holdings Inc (QTI)

$2.030

-0.039 (-1.93%)Al cierre

Loading chart…
Máximo
2.150
Apertura
2.070
Precio medio ponderado por volumen
2.06
Volumen
28.49K
Capitalización
—
Mínimo
2.010
Importe
58.78K
EV/EBITDA, TTM
-1.66

QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology.

Análisis de IA of QT Imaging Holdings Inc (QTI)

Comprar

QT Imaging Holdings Inc (QTI) presents a compelling buy opportunity at the current price of $2.03, especially considering its recent 103% revenue growth in Q2 2026, which indicates strong market demand. The RSI is at a low 19.071, suggesting the stock is oversold and may rebound. However, the main risk is the significant net income loss of $11.07 million in Q2 2026, which investors should monitor closely.

Métricas de valoración

El PER previsto actual de QT Imaging Holdings Inc (QTI) es 0.00, frente a su media de 5 años de 0.00.

PER previsto

Muy infravalorado
Media 5A P/E
0.00
P/E actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-0.96
EV/EBITDA actual
-1.66
Sobrevalorada
2.00
Infravalorada
-3.93

Precio/ventas previsto

Valor razonable
Media 5A P/S
0.18
P/S actual
0.53
Sobrevalorada
0.54
Infravalorada
-0.19

Cronología de eventos

2026-10-07 (ET)

09:00:00

QT Imaging Partners with NXC Imaging for National Purchasing Agreement

2026-09-17 (ET)

09:00:00

QT Imaging Appoints Mark Winkler as Chief Medical Officer

2026-08-12 (ET)

16:30:00

QT Imaging Reports Q2 Revenue of $7.4M, Below Estimates

2026-08-04 (ET)

09:00:00

QT Imaging Appoints New VPs to Advance U.S. Sales Strategy

2026-07-29 (ET)

09:00:00

QT Imaging Appoints Julia Albright as Chief Science Officer

Noticias

Preguntas frecuentes sobre QTI, respondidas por Alphio AI

QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology. It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).

QT Imaging Holdings Inc (QTI) presents a compelling buy opportunity at the current price of $2.03, especially considering its recent 103% revenue growth in Q2 2026, which indicates strong market demand. The RSI is at a low 19.071, suggesting the stock is oversold and may rebound. However, the main risk is the significant net income loss of $11.07 million in Q2 2026, which investors should monitor closely.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar